COLISTIMETHATE SODIUM

COLISTIMETHATE SODIUM
Product Description

SUANFARMA Group

  • ES
  • 2015
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Distributor/Import Export
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer

SUANFARMA Group

  • ES
  • 2015
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Distributor/Import Export
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer

More Products from SUANFARMA Group (14)

  • FIROCOXIB

    Product FIROCOXIB

    ANALGESIC (VETERINARY)
  • TULATHROMYCIN

    Product TULATHROMYCIN

    ANTIBIOTIC (VETERINARY)
  • QUETIAPINE FUMARATE
  • ALTRENOGEST

    Product ALTRENOGEST

    Veterinary use. It is a synthetic progestogen (sex hormone), programmer and synchronizer of the estrous cycle in swine and horses.
  • CHLORTHALIDONE

    Product CHLORTHALIDONE

    Human use. Diuretic used in the treatment of arterial hypertension and chronic stable heart failure. Diuretic and antihypertensive
  • CLOMIPHENE CITRATE

    Product CLOMIPHENE CITRATE

    OVULATION STIMULANT
  • DARUNAVIR

    Product DARUNAVIR

    Human use. Antiviral for systemic use, protease inhibitor. It is indicated for the treatment of patients with Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral drugs.
  • ANASTROZOLE
  • BISOPROLOL

    Product BISOPROLOL

    ANTIHYPERTENSIVE
  • CLOBUTINOL HCL

    Product CLOBUTINOL HCL

    ANTITUSSIVES. COUGH SUPPRESSANT
  • ENOXAPARINE SODIUM
  • RIVAROXABAN

    Product RIVAROXABAN

    ANTICOAGULANTS

SUANFARMA Group resources (5)

  • Video SUANFARMA - CORPORATE VIDEO

    SUANFARMA was born in Spain in 1993 and is specialized in the development, production and commercialization of ingredients for the pharmaceutical, veterinary, and nutritional sectors. 

    During the last 5 years the company has achieved the highest growth in its history and has acquired 5 new companies in Spain, Portugal, Colombia and Italy, increasing significantly its industrial and development capacity. SUANFARMA Group is represented by over 650 people, with presence in over 70 countries.

    At SUANFARMA, we are committed to health and innovation. We develop new technologies and processes to offer innovative products, following the trends of the world of health and the needs of our customers. We cover both “super sales” molecules and niche molecules or specialized therapies, controlling the production process from the intermediate to the final product.
  • Video Corporate video Cipan Lisbon

    Founded in 1960, Cipan is a company committed to health, and this has been demonstrated in its more than 50-year history

    Cipan has developed, either through its own investment or through CDO strategies, three generations of APIs derived from Tetracycline: Tetracycline, Minocycline, Lymecycline, Oxytetracycline, and other third-generation molecules that are currently in commercial phase (CMO) or development (CDO).

  • Video SUANNUTRA

    SUANNUTRA is a reference company in the nutraceutical ingredients sector, supporting customers by satisfying their supply needs and accompanying them in their commercial success. We are present from research and development to market launch. We offer both essential ingredients and the most select compounds, with proven scientific evidence.
  • Video CIPAN

    Founded in 1960, Cipan is a company committed to health, and this has been demonstrated in its more than 50-year history

    Cipan has developed, either through its own investment or through CDO strategies, three generations of APIs derived from Tetracycline: Tetracycline, Minocycline, Lymecycline, Oxytetracycline, and other third-generation molecules that are currently in commercial phase (CMO) or development (CDO).

  • Video CIPAN

    Founded in 1960, Cipan is a company committed to health, and this has been demonstrated in its more than 50-year history

    Cipan has developed, either through its own investment or through CDO strategies, three generations of APIs derived from Tetracycline: Tetracycline, Minocycline, Lymecycline, Oxytetracycline, and other third-generation molecules that are currently in commercial phase (CMO) or development (CDO).